Renal Biomarkers Market Size, Share & Trends Analysis Report By Biomarkers (Functional Biomarkers, Upregulated Proteins), By Diagnostic Technique (ELISA, Immunoassays), By End Use (Hospitals & Clinics), By Region, And Segment Forecasts, 2025

The global renal biomarkers market size was estimated at USD 1,530.0 million in 2024 and is expected to reach USD 3,161.4 million by 2033, growing at a CAGR of 8.54% from 2025 to 2033. The rising prevalence of kidney disease particularly chronic kidney disease (CKD) and acute kidney injury (AKI) along with the urgent clinical need for earlier and more nuanced detection beyond conventional measures.

CKD often remains asymptomatic until advanced stages, and biomarkers that can reveal subclinical pathology or early injury are of growing interest. In the U.S., an estimated 35.5 million adults have chronic kidney disease (CKD), and a significant number are unaware of their condition. Globally, CKD affects around 850 million people, which is approximately 9% of the adult population. A 2024 study projects that by 2032, nearly 125 million people across eight major countries will have advanced CKD, a 25% increase since 2022. In April 2024, AstraZeneca's IMPACT CKD modeling study projected that by 2032, as many as 16.5% of the population across eight countries could be affected by chronic kidney disease (CKD), with advanced-stage cases potentially increasing by up to 59.3%. The findings, presented at the 2024 ISN World Congress of Nephrology (WCN'24) in Buenos Aires, underscored the escalating global health challenge posed by CKD and emphasized its significant economic and environmental consequences. The large and growing base of kidney disease patients ensures a continually rising demand for more sensitive, specific, and multiplex biomarker assays. In addition, co-morbidities such as diabetes, hypertension, and aging populations further exacerbate kidney stress, pushing clinicians and payers to adopt advanced biomarkers (e.g. NGAL, KIM-1, cystatin C) earlier in the disease continuum to improve prognostics, therapy stratification, and monitoring. The high rate of undiagnosed early CKD (sometimes up to 90 % of cases go unnoticed until functional decline) underscores the latent market potential for tools that reliably flag early damage before conventional metrics (eGFR, creatinine) deviate significantly.

One of the most compelling opportunities in the renal biomarker landscape lies in emerging markets-Asia, Latin America, Africa where rising incidence of hypertension, diabetes, and aging populations is intensifying the renal disease burden, yet diagnostic infrastructure remains underdeveloped. As diagnostics penetration is still relatively low in many of these geographies, the entry of affordable, point-of-care biomarker platforms offers a high-growth niche. For example, Sphingotec's collaborations (e.g. with Beckman Coulter) to release penKid assays on standard clinical lab platforms reflect how a biomarker originally confined to research can scale into broader clinical adoption. (See news of licensing and launch of penKid in central labs) The capacity to deploy multiplex panels, low-volume assays, or simpler rapid tests in decentralized settings could help bridge diagnostic gaps in underserved regions.

Meanwhile, platform diversity is growing enzyme-linked immunosorbent assays (ELISA) still command a significant share, but more sensitive chemiluminescent immunoassays, multiplex panels, mass spectrometry (LC-MS), microfluidics, and point-of-care immunodiagnostic devices are gaining traction. For instance, the penKid assay's adoption on Beckman Coulter immunoassay platforms exemplifies how a novel biomarker can be integrated lab workflows. In research settings, microfluidic and multi-omics platforms will support novel discovery and multiplex panels opening scope for biomarker companies to offer value-added analytics, software, and interpretation services.

Global Renal Biomarkers Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global renal biomarkers market based on biomarker, diagnostic technique, end use, and region:

Biomarkers Outlook (Revenue, USD Million, 2021 - 2033)
Kits and reagents
Functional Biomarkers
- Serum Creatinine
- Blood Urea Nitrogen (BUN)
- Estimated Glomerular Filtration Rate (eGFR)
Upregulated Proteins
- Kidney Injury Molecule-1 (KIM-1)
- Neutrophil Gelatinase-Associated Lipocalin (NGAL)
- Cystatin C
- Interleukin-18 (IL-18)
- Others
Other Novel Biomarkers
- microRNA biomarkers
- Proteomic/metabolomic markers
Diagnostic technique/Platform Outlook (Revenue, USD Million, 2021 - 2033)
Enzyme-Linked Immunosorbent Assay (ELISA)
Immunoassays
Clinical Chemistry Assays
Point-of-Care Testing (POCT) Devices
Molecular Diagnostics
Other Emerging Platforms
End Use Outlook (Revenue, USD Million, 2021 - 2033)
Hospitals & Clinics
Diagnostic Laboratories
Academic & Research Institutes
Pharmaceutical & Biotechnology Companies
Others
Regional Outlook (Revenue, USD Million, 2021 - 2033)
North America
- U.S.
- Canada
- Mexico
Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
Latin America
- Brazil
- Argentina
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait

Product Code: GVR-4-68040-764-4

Chapter 1. Renal Biomarkers Market: Methodology and Scope

1.1. Market Segmentation and Scope
- 1.1.1. Segment Definitions
  - 1.1.1.1. Biomarkers Segment
  - 1.1.1.2. Diagnostic Technique/Platform Segment
  - 1.1.1.3. End Use Segment
1.2. Regional Scope
1.3. Estimates and Forecast Timeline
1.4. Objectives
- 1.4.1. Objective - 1
- 1.4.2. Objective - 2
- 1.4.3. Objective - 3
1.5. Research Methodology
1.6. Information Procurement
- 1.6.1. Purchased Database
- 1.6.2. GVR's Internal Database
- 1.6.3. Secondary Sources
- 1.6.4. Primary Research
1.7. Information or Data Analysis
- 1.7.1. Data Analysis Models
1.8. Market Formulation & Validation
1.9. Model Details
- 1.9.1. Commodity Flow Analysis
1.10. List of Secondary Sources
1.11. List of Abbreviations

Chapter 2. Renal Biomarkers Market: Executive Summary

2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot

Chapter 3. Renal Biomarkers Market Variables, Trends, & Scope

3.1. Market Segmentation and Scope
3.2. Market Lineage Outlook
- 3.2.1. Parent Market Outlook
- 3.2.2. Related/Ancillary Market Outlook
3.3. Market Dynamics
- 3.3.1. Market driver analysis
  - 3.3.1.1. Rising prevalence of kidney diseases:
  - 3.3.1.2. Government Initiatives and Health Awareness Programs
  - 3.3.1.3. Technological advancements in kidney diagnostics
- 3.3.2. Market restraint analysis
  - 3.3.2.1. High cost of diagnostics test
  - 3.3.2.2. Limited availability of trained personnel to perform and interpret biomarker tests
3.4. Global Biomarker-Based Immunoassays Market Analysis Tools
- 3.4.1. Industry Analysis - Porter's
- 3.4.2. PESTEL Analysis

Chapter 4. Renal Biomarkers Market: Biomarkers Estimates & Trend Analysis

4.1. Renal Biomarkers Market: Biomarkers Movement Analysis
4.2. Kits and assays
- 4.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.3. Reagents
- 4.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.4. Services
- 4.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.5. Functional Biomarkers
- 4.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.5.2. Serum Creatinine
  - 4.5.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.5.3. Blood Urea Nitrogen (BUN)
  - 4.5.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.5.4. Estimated Glomerular Filtration Rate (eGFR)
  - 4.5.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.6. Upregulated Proteins
- 4.6.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.6.2. Kidney Injury Molecule-1 (KIM-1)
  - 4.6.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.6.3. Neutrophil Gelatinase-Associated Lipocalin (NGAL)
  - 4.6.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.6.4. Cystatin C
  - 4.6.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.6.5. Interleukin-18 (IL-18)
  - 4.6.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.6.6. Others
  - 4.6.6.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.7. Other Novel Biomarkers
- 4.7.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.7.2. microRNA biomarkers
  - 4.7.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.7.3. Proteomic/metabolomic markers
  - 4.7.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Renal Biomarkers Market: Diagnostic Technique/Platform Estimates & Trend Analysis

5.1. Renal Biomarkers Market: Diagnostic Technique/Platform Movement Analysis
5.2. Enzyme-Linked Immunosorbent Assay (ELISA)
- 5.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.3. Molecular Diagnostics
- 5.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.4. Immunoassays
- 5.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.5. Clinical Chemistry Assays
- 5.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.6. Point-of-Care Testing (POCT) Devices
- 5.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.7. Other Emerging Platforms
- 5.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Renal Biomarkers Market: End Use Estimates & Trend Analysis

6.1. Renal Biomarkers Market: End Use Movement Analysis
6.2. Hospitals and clinics
- 6.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
6.3. Diagnostics Laboratories
- 6.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
6.4. Academic & Research Institutes
- 6.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5. Pharmaceutical & Biotechnology Companies
- 6.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6. Others
- 6.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Renal Biomarkers Market: Regional Business Analysis

7.1. Regional Market Snapshot
7.2. North America
- 7.2.1. North America Renal Biomarkers Market Estimates And Forecast, 2021 - 2033 (USD Million)
- 7.2.2. U.S.
  - 7.2.2.1. U.S. Renal Biomarkers Market, 2021 - 2033 (USD Million)
  - 7.2.2.2. Key Country Dynamics
  - 7.2.2.3. Regulatory Framework
  - 7.2.2.4. Reimbursement Scenario
  - 7.2.2.5. Competitive Scenario
- 7.2.3. Canada
  - 7.2.3.1. Canada Renal Biomarkers Market, 2021 - 2033 (USD Million)
  - 7.2.3.2. Key Country Dynamics
  - 7.2.3.3. Regulatory Framework
  - 7.2.3.4. Reimbursement Scenario
  - 7.2.3.5. Competitive Scenario
- 7.2.4. Mexico
  - 7.2.4.1. Mexico Renal Biomarkers Market, 2021 - 2033 (USD Million)
  - 7.2.4.2. Key Country Dynamics
  - 7.2.4.3. Regulatory Framework
  - 7.2.4.4. Reimbursement Scenario
  - 7.2.4.5. Competitive Scenario
7.3. Europe
- 7.3.1. Europe Renal Biomarkers Market, 2021 - 2033 (USD Million)
- 7.3.2. UK
  - 7.3.2.1. UK Renal Biomarkers Market, 2021 - 2033 (USD Million)
  - 7.3.2.2. Key Country Dynamics
  - 7.3.2.3. Regulatory Framework
  - 7.3.2.4. Reimbursement Scenario
  - 7.3.2.5. Competitive Scenario
- 7.3.3. Germany
  - 7.3.3.1. Germany Renal Biomarkers Market, 2021 - 2033 (USD Million)
  - 7.3.3.2. Key Country Dynamics
  - 7.3.3.3. Regulatory Framework
  - 7.3.3.4. Reimbursement Scenario
  - 7.3.3.5. Competitive Scenario
- 7.3.4. Spain
  - 7.3.4.1. Spain Renal Biomarkers Market, 2021 - 2033 (USD Million)
  - 7.3.4.2. Key Country Dynamics
  - 7.3.4.3. Regulatory Framework
  - 7.3.4.4. Reimbursement Scenario
  - 7.3.4.5. Competitive Scenario
- 7.3.5. France
  - 7.3.5.1. France Renal Biomarkers Market, 2021 - 2033 (USD Million)
  - 7.3.5.2. Key Country Dynamics
  - 7.3.5.3. Regulatory Framework
  - 7.3.5.4. Reimbursement Scenario
  - 7.3.5.5. Competitive Scenario
- 7.3.6. Italy
  - 7.3.6.1. Italy Renal Biomarkers Market, 2021 - 2033 (USD Million)
  - 7.3.6.2. Key Country Dynamics
  - 7.3.6.3. Regulatory Framework
  - 7.3.6.4. Reimbursement Scenario
  - 7.3.6.5. Competitive Scenario
- 7.3.7. Denmark
  - 7.3.7.1. Denmark Renal Biomarkers Market, 2021 - 2033 (USD Million)
  - 7.3.7.2. Key Country Dynamics
  - 7.3.7.3. Regulatory Framework
  - 7.3.7.4. Reimbursement Scenario
  - 7.3.7.5. Competitive Scenario
- 7.3.8. Sweden
  - 7.3.8.1. Sweden Renal Biomarkers Market, 2021 - 2033 (USD Million)
  - 7.3.8.2. Key Country Dynamics
  - 7.3.8.3. Regulatory Framework
  - 7.3.8.4. Reimbursement Scenario
  - 7.3.8.5. Competitive Scenario
- 7.3.9. Norway
  - 7.3.9.1. Norway Renal Biomarkers Market, 2021 - 2033 (USD Million)
  - 7.3.9.2. Key Country Dynamics
  - 7.3.9.3. Regulatory Framework
  - 7.3.9.4. Reimbursement Scenario
  - 7.3.9.5. Competitive Scenario
7.4. Asia Pacific
- 7.4.1. Asia-Pacific Renal Biomarkers Market, 2021 - 2033 (USD Million)
- 7.4.2. Japan
  - 7.4.2.1. Japan Renal Biomarkers Market, 2021 - 2033 (USD Million)
  - 7.4.2.2. Key Country Dynamics
  - 7.4.2.3. Regulatory Framework
  - 7.4.2.4. Reimbursement Scenario
  - 7.4.2.5. Competitive Scenario
- 7.4.3. China
  - 7.4.3.1. China Renal Biomarkers Market, 2021 - 2033 (USD Million)
  - 7.4.3.2. Key Country Dynamics
  - 7.4.3.3. Regulatory Framework
  - 7.4.3.4. Reimbursement Scenario
  - 7.4.3.5. Competitive Scenario
- 7.4.4. India
  - 7.4.4.1. India Renal Biomarkers Market, 2021 - 2033 (USD Million)
  - 7.4.4.2. Key Country Dynamics
  - 7.4.4.3. Regulatory Framework
  - 7.4.4.4. Reimbursement Scenario
  - 7.4.4.5. Competitive Scenario
- 7.4.5. South Korea
  - 7.4.5.1. South Korea Renal Biomarkers Market, 2021 - 2033 (USD Million)
  - 7.4.5.2. Key Country Dynamics
  - 7.4.5.3. Regulatory Framework
  - 7.4.5.4. Reimbursement Scenario
  - 7.4.5.5. Competitive Scenario
- 7.4.6. Thailand
  - 7.4.6.1. Thailand Renal Biomarkers Market, 2021 - 2033 (USD Million)
  - 7.4.6.2. Key Country Dynamics
  - 7.4.6.3. Regulatory Framework
  - 7.4.6.4. Reimbursement Scenario
  - 7.4.6.5. Competitive Scenario
- 7.4.7. Australia
  - 7.4.7.1. Australia Renal Biomarkers Market, 2021 - 2033 (USD Million)
  - 7.4.7.2. Key Country Dynamics
  - 7.4.7.3. Regulatory Framework
  - 7.4.7.4. Reimbursement Scenario
  - 7.4.7.5. Competitive Scenario
7.5. Latin America
- 7.5.1. Latin America Renal Biomarkers Market, 2021 - 2033 (USD Million)
- 7.5.2. Brazil
  - 7.5.2.1. Brazil Renal Biomarkers Market, 2021 - 2033 (USD Million)
  - 7.5.2.2. Key Country Dynamics
  - 7.5.2.3. Regulatory Framework
  - 7.5.2.4. Reimbursement Scenario
  - 7.5.2.5. Competitive Scenario
- 7.5.3. Argentina
  - 7.5.3.1. Argentina Renal Biomarkers Market, 2021 - 2033 (USD Million)
  - 7.5.3.2. Key Country Dynamics
  - 7.5.3.3. Regulatory Framework
  - 7.5.3.4. Reimbursement Scenario
  - 7.5.3.5. Competitive Scenario
7.6. MEA
- 7.6.1. MEA Renal Biomarkers Market, 2021 - 2033 (USD Million)
- 7.6.2. South Africa
  - 7.6.2.1. South Africa Renal Biomarkers Market, 2021 - 2033 (USD Million)
  - 7.6.2.2. Key Country Dynamics
  - 7.6.2.3. Regulatory Framework
  - 7.6.2.4. Reimbursement Scenario
  - 7.6.2.5. Competitive Scenario
- 7.6.3. Saudi Arabia
  - 7.6.3.1. Saudi Arabia Renal Biomarkers Market, 2021 - 2033 (USD Million)
  - 7.6.3.2. Key Country Dynamics
  - 7.6.3.3. Regulatory Framework
  - 7.6.3.4. Reimbursement Scenario
  - 7.6.3.5. Competitive Scenario
- 7.6.4. UAE
  - 7.6.4.1. UAE Renal Biomarkers Market, 2021 - 2033 (USD Million)
  - 7.6.4.2. Key Country Dynamics
  - 7.6.4.3. Regulatory Framework
  - 7.6.4.4. Reimbursement Scenario
  - 7.6.4.5. Competitive Scenario
- 7.6.5. Kuwait
  - 7.6.5.1. Kuwait Renal Biomarkers Market, 2021 - 2033 (USD Million)
  - 7.6.5.2. Key Country Dynamics
  - 7.6.5.3. Regulatory Framework
  - 7.6.5.4. Reimbursement Scenario
  - 7.6.5.5. Competitive Scenario

Chapter 8. Competitive Landscape

8.1. Company Categorization
8.2. Strategy Mapping
- 8.2.1. New Biomarkers Launch
- 8.2.2. Partnerships
- 8.2.3. Acquisition
- 8.2.4. Collaboration
- 8.2.5. Funding
8.3. Key Company Market Share Analysis, 2024
8.4. Company Heat Map Analysis
8.5. Company Profiles
- 8.5.1. Thermo Fisher Scientific Inc.
  - 8.5.1.1. Company Overview
  - 8.5.2.2. Financial Performance
  - 8.5.2.3. Biomarkers Benchmarking
  - 8.5.2.4. Strategic Initiatives
- 8.5.2. Siemens Healthineers AG
  - 8.5.2.1. Company Overview
  - 8.5.2.2. Financial Performance
  - 8.5.2.3. Biomarkers Benchmarking
  - 8.5.2.4. Strategic Initiatives
- 8.5.3. BioPorto Diagnostics A/S
  - 8.5.3.1. Company Overview
  - 8.5.3.2. Financial Performance
  - 8.5.3.3. Biomarkers Benchmarking
  - 8.5.3.4. Strategic Initiatives
- 8.5.4. SEKISUI Medical Co., Ltd
  - 8.5.4.1. Company Overview
  - 8.5.4.2. Financial Performance
  - 8.5.4.3. Biomarkers Benchmarking
  - 8.5.4.4. Strategic Initiatives
- 8.5.5. BioMerieux SA
  - 8.5.5.1. Company Overview
  - 8.5.5.2. Financial Performance
  - 8.5.5.3. Biomarkers Benchmarking
  - 8.5.5.4. Strategic Initiatives
- 8.5.6. SphingoTec GmbH
  - 8.5.6.1. Company Overview
  - 8.5.6.2. Financial Performance
  - 8.5.6.3. Biomarkers Benchmarking
  - 8.5.6.4. Strategic Initiatives
- 8.5.7. Randox Laboratories Ltd
  - 8.5.7.1. Company Overview
  - 8.5.7.2. Financial Performance
  - 8.5.7.3. Biomarkers Benchmarking
  - 8.5.7.4. Strategic Initiatives
- 8.5.8. Beckman Coulter Inc.
  - 8.5.8.1. Company Overview
  - 8.5.8.2. Financial Performance
  - 8.5.8.3. Biomarkers Benchmarking
  - 8.5.8.4. Strategic Initiatives
- 8.5.9. QIAGEN N.V.
  - 8.5.9.1. Company Overview
  - 8.5.9.2. Financial Performance
  - 8.5.9.3. Biomarkers Benchmarking
  - 8.5.9.4. Strategic Initiatives
- 8.5.10. EKF Diagnostics Holdings plc
  - 8.5.10.1. Company Overview
  - 8.5.10.2. Financial Performance
  - 8.5.10.3. Biomarkers Benchmarking
  - 8.5.10.4. Strategic Initiatives

Product Code: GVR-4-68040-764-4

List of Tables

Table 1 List Of Secondary Sources
Table 2 List Of Abbreviation
Table 3 Global Renal Biomarkers Market, By Region, 2021 - 2033 (USD Million)
Table 4 Global Renal Biomarkers Market, By Biomarkers, 2021 - 2033 (USD Million)
Table 5 Global Renal Biomarkers Market, By Diagnostic Technique/Platform, 2021 - 2033 (USD Million)
Table 6 Global Renal Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
Table 7 North America Renal Biomarkers Market, By Country, 2021 - 2033 (USD Million)
Table 8 North America Renal Biomarkers Market, By Biomarkers, 2021 - 2033 (USD Million)
Table 9 North America Renal Biomarkers Market, By Diagnostic Technique/Platform, 2021 - 2033 (USD Million)
Table 10 North America Renal Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
Table 11 U.S. Renal Biomarkers Market, By Biomarkers, 2021 - 2033 (USD Million)
Table 12 U.S. Renal Biomarkers Market, By Diagnostic Technique/Platform, 2021 - 2033 (USD Million)
Table 13 U.S. Renal Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
Table 14 Canada Renal Biomarkers Market, By Biomarkers, 2021 - 2033 (USD Million)
Table 15 Canada Renal Biomarkers Market, By Diagnostic Technique/Platform, 2021 - 2033 (USD Million)
Table 16 Canada Renal Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
Table 17 Mexico Renal Biomarkers Market, By Biomarkers, 2021 - 2033 (USD Million)
Table 18 Mexico Renal Biomarkers Market, By Diagnostic Technique/Platform, 2021 - 2033 (USD Million)
Table 19 Mexico Renal Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
Table 20 Europe Renal Biomarkers Market, By Country, 2021 - 2033 (USD Million)
Table 21 Europe Renal Biomarkers Market, By Biomarkers, 2021 - 2033 (USD Million)
Table 22 Europe Renal Biomarkers Market, By Diagnostic Technique/Platform, 2021 - 2033 (USD Million)
Table 23 Europe Renal Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
Table 24 UK Renal Biomarkers Market, By Biomarkers, 2021 - 2033 (USD Million)
Table 25 UK Renal Biomarkers Market, By Diagnostic Technique/Platform, 2021 - 2033 (USD Million)
Table 26 UK Renal Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
Table 27 Germany Renal Biomarkers Market, By Biomarkers, 2021 - 2033 (USD Million)
Table 28 Germany Renal Biomarkers Market, By Diagnostic Technique/Platform, 2021 - 2033 (USD Million)
Table 29 Germany Renal Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
Table 30 France Renal Biomarkers Market, By Biomarkers, 2021 - 2033 (USD Million)
Table 31 France Renal Biomarkers Market, By Diagnostic Technique/Platform, 2021 - 2033 (USD Million)
Table 32 France Renal Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
Table 33 Italy Renal Biomarkers Market, By Biomarkers, 2021 - 2033 (USD Million)
Table 34 Italy Renal Biomarkers Market, By Diagnostic Technique/Platform, 2021 - 2033 (USD Million)
Table 35 Italy Renal Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
Table 36 Spain Renal Biomarkers Market, By Biomarkers, 2021 - 2033 (USD Million)
Table 37 Spain Renal Biomarkers Market, By Diagnostic Technique/Platform, 2021 - 2033 (USD Million)
Table 38 Spain Renal Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
Table 39 Sweden Renal Biomarkers Market, By Biomarkers, 2021 - 2033 (USD Million)
Table 40 Sweden Renal Biomarkers Market, By Diagnostic Technique/Platform, 2021 - 2033 (USD Million)
Table 41 Sweden Renal Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
Table 42 Norway Renal Biomarkers Market, By Biomarkers, 2021 - 2033 (USD Million)
Table 43 Norway Renal Biomarkers Market, By Diagnostic Technique/Platform, 2021 - 2033 (USD Million)
Table 44 Norway Renal Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
Table 45 Denmark Renal Biomarkers Market, By Biomarkers, 2021 - 2033 (USD Million)
Table 46 Denmark Renal Biomarkers Market, By Diagnostic Technique/Platform, 2021 - 2033 (USD Million)
Table 47 Denmark Renal Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
Table 48 Asia Pacific Renal Biomarkers Market, By Country, 2021 - 2033 (USD Million)
Table 49 Asia Pacific Renal Biomarkers Market, By Biomarkers, 2021 - 2033 (USD Million)
Table 50 Asia Pacific Renal Biomarkers Market, By Diagnostic Technique/Platform, 2021 - 2033 (USD Million)
Table 51 Asia Pacific Renal Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
Table 52 Japan Renal Biomarkers Market, By Biomarkers, 2021 - 2033 (USD Million)
Table 53 Japan Renal Biomarkers Market, By Diagnostic Technique/Platform, 2021 - 2033 (USD Million)
Table 54 Japan Renal Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
Table 55 China Renal Biomarkers Market, By Biomarkers, 2021 - 2033 (USD Million)
Table 56 China Renal Biomarkers Market, By Diagnostic Technique/Platform, 2021 - 2033 (USD Million)
Table 57 China Renal Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
Table 58 India Renal Biomarkers Market, By Biomarkers, 2021 - 2033 (USD Million)
Table 59 India Renal Biomarkers Market, By Diagnostic Technique/Platform, 2021 - 2033 (USD Million)
Table 60 India Renal Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
Table 61 Australia Renal Biomarkers Market, By Biomarkers, 2021 - 2033 (USD Million)
Table 62 Australia Renal Biomarkers Market, By Diagnostic Technique/Platform, 2021 - 2033 (USD Million)
Table 63 Australia Renal Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
Table 64 Thailand Renal Biomarkers Market, By Biomarkers, 2021 - 2033 (USD Million)
Table 65 Thailand Renal Biomarkers Market, By Diagnostic Technique/Platform, 2021 - 2033 (USD Million)
Table 66 Thailand Renal Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
Table 67 South Korea Renal Biomarkers Market, By Biomarkers, 2021 - 2033 (USD Million)
Table 68 South Korea Renal Biomarkers Market, By Diagnostic Technique/Platform, 2021 - 2033 (USD Million)
Table 69 South Korea Renal Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
Table 70 Latin America Renal Biomarkers Market, By Country, 2021 - 2033 (USD Million)
Table 71 Latin America Renal Biomarkers Market, By Biomarkers, 2021 - 2033 (USD Million)
Table 72 Latin America Renal Biomarkers Market, By Diagnostic Technique/Platform, 2021 - 2033 (USD Million)
Table 73 Latin America Renal Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
Table 74 Brazil Renal Biomarkers Market, By Biomarkers, 2021 - 2033 (USD Million)
Table 75 Brazil Renal Biomarkers Market, By Diagnostic Technique/Platform, 2021 - 2033 (USD Million)
Table 76 Brazil Renal Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
Table 77 Argentina Renal Biomarkers Market, By Biomarkers, 2021 - 2033 (USD Million)
Table 78 Argentina Renal Biomarkers Market, By Diagnostic Technique/Platform, 2021 - 2033 (USD Million)
Table 79 Argentina Renal Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
Table 80 MEA Renal Biomarkers Market, By Country, 2021 - 2033 (USD Million)
Table 81 MEA Renal Biomarkers Market, By Biomarkers, 2021 - 2033 (USD Million)
Table 82 MEA Renal Biomarkers Market, By Diagnostic Technique/Platform, 2021 - 2033 (USD Million)
Table 83 MEA Renal Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
Table 84 South Africa Renal Biomarkers Market, By Biomarkers, 2021 - 2033 (USD Million)
Table 85 South Africa Renal Biomarkers Market, By Diagnostic Technique/Platform, 2021 - 2033 (USD Million)
Table 86 South Africa Renal Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
Table 87 Saudi Arabia Renal Biomarkers Market, By Biomarkers, 2021 - 2033 (USD Million)
Table 88 Saudi Arabia Renal Biomarkers Market, By Diagnostic Technique/Platform, 2021 - 2033 (USD Million)
Table 89 Saudi Arabia Renal Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
Table 90 UAE Renal Biomarkers Market, By Biomarkers, 2021 - 2033 (USD Million)
Table 91 UAE Renal Biomarkers Market, By Diagnostic Technique/Platform, 2021 - 2033 (USD Million)
Table 92 UAE Renal Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
Table 93 Kuwait Renal Biomarkers Market, By Biomarkers, 2021 - 2033 (USD Million)
Table 94 Kuwait Renal Biomarkers Market, By Diagnostic Technique/Platform, 2021 - 2033 (USD Million)
Table 95 Kuwait Renal Biomarkers Market, By End Use, 2021 - 2033 (USD Million)

List of Figures

Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Market summary
Fig. 4 Market segmentation & scope
Fig. 5 Market size and growth prospects
Fig. 6 Global renal biomarkers market- Key market driver analysis
Fig. 7 Global renal biomarkers market - Key market restraint analysis
Fig. 8 Penetration & growth prospect mapping
Fig. 9 Global renal biomarkers market - Porter's analysis
Fig. 10 Global renal biomarkers market - PESTEL analysis
Fig. 11 Global renal biomarkers market Biomarkers outlook key takeaways
Fig. 12 Global renal biomarkers market: Biomarkers movement analysis
Fig. 13 Functional Biomarkers market estimates, 2021 - 2033 (USD Million)
Fig. 14 Serum Creatinine market estimates, 2021 - 2033 (USD Million)
Fig. 15 Blood Urea Nitrogen (BUN) market estimates, 2021 - 2033 (USD Million)
Fig. 16 Estimated Glomerular Filtration Rate (eGFR) market estimates, 2021 - 2033 (USD Million)
Fig. 17 Upregulated Proteins market estimates, 2021 - 2033 (USD Million)
Fig. 18 Kidney Injury Molecule-1 (KIM-1) market estimates, 2021 - 2033 (USD Million)
Fig. 19 Neutrophil Gelatinase-Associated Lipocalin (NGAL) market estimates, 2021 - 2033 (USD Million)
Fig. 20 Cystatin C market estimates, 2021 - 2033 (USD Million)
Fig. 21 Interleukin-18 (IL-18) market estimates, 2021 - 2033 (USD Million)
Fig. 22 Others market estimates, 2021 - 2033 (USD Million)
Fig. 23 Other Novel Biomarkers market estimates, 2021 - 2033 (USD Million)
Fig. 24 microRNA biomarkers market estimates, 2021 - 2033 (USD Million)
Fig. 25 Proteomic/metabolomic markers Global renal biomarkers market technology outlook key takeaways
Fig. 26 Global renal biomarkers market: diagnostic technique/platform movement analysis
Fig. 27 Immunoassays market estimates, 2021 - 2033 (USD Million)
Fig. 28 Molecular diagnostics market estimates, 2021 - 2033 (USD Million)
Fig. 29 ELISA market estimates, 2021 - 2033 (USD Million)
Fig. 30 Clinical chemistry assays market estimates, 2021 - 2033 (USD Million)
Fig. 31 POCT market estimates, 2021 - 2033 (USD Million)
Fig. 32 Global renal biomarkers market end use outlook key takeaways
Fig. 33 Global renal biomarkers market: end use movement analysis
Fig. 34 Hospitals and diagnostics laboratories market estimates, 2021 - 2033 (USD Million)
Fig. 35 Diagnostic laboratories market estimates, 2021 - 2033 (USD Million)
Fig. 36 Academic & Research Institutes market estimates, 2021 - 2033 (USD Million)
Fig. 37 Pharmaceutical & biotechnology companies market estimates, 2021 - 2033 (USD Million)
Fig. 38 Others market estimates, 2021 - 2033 (USD Million)
Fig. 39 Regional marketplace: Key takeaways
Fig. 40 Global Renal Biomarkers market: Regional movement analysis
Fig. 41 North America Renal Biomarkers market, 2021 - 2033 (USD Million)
Fig. 42 U.S. renal biomarkers market, 2021 - 2033 (USD Million)
Fig. 43 Canada renal biomarkers market, 2021 - 2033 (USD Million)
Fig. 44 Mexico renal biomarkers market, 2021 - 2033 (USD Million)
Fig. 45 Europe renal biomarkers market, 2021 - 2033 (USD Million)
Fig. 46 UK renal biomarkers market, 2021 - 2033 (USD Million)
Fig. 47 Germany renal biomarkers market, 2021 - 2033 (USD Million)
Fig. 48 France renal biomarkers market, 2021 - 2033 (USD Million)
Fig. 49 Spain renal biomarkers market, 2021 - 2033 (USD Million)
Fig. 50 Italy renal biomarkers market, 2021 - 2033 (USD Million)
Fig. 51 Denmark renal biomarkers market, 2021 - 2033 (USD Million)
Fig. 52 Sweden renal biomarkers market, 2021 - 2033 (USD Million)
Fig. 53 Norway renal biomarkers market, 2021 - 2033 (USD Million)
Fig. 54 Asia Pacific renal biomarkers market, 2021 - 2033 (USD Million)
Fig. 55 Japan renal biomarkers market, 2021 - 2033 (USD Million)
Fig. 56 China renal biomarkers market, 2021 - 2033 (USD Million)
Fig. 57 India renal biomarkers market, 2021 - 2033 (USD Million)
Fig. 58 South Korea renal biomarkers market, 2021 - 2033 (USD Million)
Fig. 59 Australia renal biomarkers market, 2021 - 2033 (USD Million)
Fig. 60 Thailand renal biomarkers market, 2021 - 2033 (USD Million)
Fig. 61 Latin America renal biomarkers market, 2021 - 2033 (USD Million)
Fig. 62 Brazil renal biomarkers market, 2021 - 2033 (USD Million)
Fig. 63 Argentina renal biomarkers market, 2021 - 2033 (USD Million)
Fig. 64 MEA renal biomarkers market, 2021 - 2033 (USD Million)
Fig. 65 South Africa renal biomarkers market, 2021 - 2033 (USD Million)
Fig. 66 Saudi Arabia renal biomarkers market, 2021 - 2033 (USD Million)
Fig. 67 UAE renal biomarkers market, 2021 - 2033 (USD Million)
Fig. 68 Kuwait renal biomarkers market, 2021 - 2033 (USD Million)
Fig. 69 Strategy framework

Renal Biomarkers Market Size, Share & Trends Analysis Report By Biomarkers (Functional Biomarkers, Upregulated Proteins), By Diagnostic Technique (ELISA, Immunoassays), By End Use (Hospitals & Clinics), By Region, And Segment Forecasts, 2025 - 2033

Description

Table of Contents

List of Tables

Renal Biomarkers Market Summary

Table of Contents

Chapter 1. Renal Biomarkers Market: Methodology and Scope

Chapter 2. Renal Biomarkers Market: Executive Summary

Chapter 3. Renal Biomarkers Market Variables, Trends, & Scope

Chapter 4. Renal Biomarkers Market: Biomarkers Estimates & Trend Analysis

Chapter 5. Renal Biomarkers Market: Diagnostic Technique/Platform Estimates & Trend Analysis

Chapter 6. Renal Biomarkers Market: End Use Estimates & Trend Analysis

Chapter 7. Renal Biomarkers Market: Regional Business Analysis

Chapter 8. Competitive Landscape

List of Tables

List of Figures